Drug Profile
SIM 0930
Alternative Names: SIM-0930Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Simcere Pharmaceutical Group
- Developer Astellas Pharma; Simcere Pharmaceutical Group
- Class
- Mechanism of Action Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in China
- 14 Aug 2015 SIM 0930 is at the IND stage for Cancer in China